Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2011, Article ID 714978, 4 pages
http://dx.doi.org/10.1155/2011/714978
Clinical Study

The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents

1Department of Urology, Sapporo Medical University School of Medicine, Sapporo 060-8543, Japan
2Furuya Hospital, Urology service, Kitami 090-0065, Japan
3Iwasawa Clinic, Urology service, Sapporo 060-0061, Japan
4Nisshin Urological Clinic, Urology service, Tomakomai 053-0833, Japan
5NTT East Japan Sapporo Hospital, Division of Urology, Sapporo 060-0061, Japan
6Kaguraoka Urological Clinic, Urology service, Asahikawa 078-8315, Japan
7Kiyota Urological Clinic, Urology service, Sapporo 004-0841, Japan

Received 19 April 2011; Accepted 5 May 2011

Academic Editor: Yasuhiko Igawa

Copyright © 2011 Naoya Masumori et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Abrams, L. Cardozo, M. Fall et al., “The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society,” Neurourology and Urodynamics, vol. 21, no. 2, pp. 167–178, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Homma, O. Yamaguchi, and K. Hayashi, “An epidemiological survey of overactive bladder symptoms in Japan,” British Journal of Urology International, vol. 96, no. 9, pp. 1314–1318, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. O. Yamaguchi, O. Nishizawa, M. Takeda et al., “Clinical guidelines for overactive bladder,” International Journal of Urology, vol. 16, no. 2, pp. 126–142, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Haruno, Y. Yamasaki, K. Miyoshi et al., “Effects of propiverine and its metabolites on isolated guinea pig urinary bladder,” Folia Pharmacol Japan, vol. 94, pp. 145–150, 1989. View at Google Scholar
  5. M. Stohrer, G. Murtz, G. Kramer, F. Schnabel, E. P. Arnold, and J. J. Wyndaele, “Propiverine compared to oxybutynin in neurogenic detrusor overactivity: results of a randomized, double-blind, multicenter clinical study,” European Urology, vol. 51, no. 1, pp. 235–242, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Homma, M. Yoshida, N. Seki et al., “Symptom assessment tool for overactive bladder syndrome: overactive bladder symptom score,” Urology, vol. 68, no. 2, pp. 318–323, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Yamada, Y. Kobayashi, and T. Aita, “Effect of propiverine on the atropine-resistant contraction of urinary bladders in aged rats,” Yamagata Medical Journal, vol. 26, pp. 53–60, 2008. View at Google Scholar
  8. K. E. Anderson, “Pharmacology of lower urinary tract smooth muscles and penile erectile tissues,” Pharmacological Reviews, vol. 45, no. 3, pp. 253–308, 1993. View at Google Scholar · View at Scopus
  9. Y. Sugiyama, M. Yoshida, K. Masunaga et al., “Pharmacological effects of propiverine and its active metabolite, M-1, on isolated human urinary bladder smooth muscle, and on bladder contraction in rats,” International Journal of Urology, vol. 15, no. 1, pp. 76–81, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Itoh and T. Nishi, “Post marketing surveillance of propiverine hydrochloride (BUP-4 tablets) in pollakiuria and urinary incontinence,” Japanese Pharmacology and Therapeutics, vol. 30, no. 12, pp. 1023–1036, 2002. View at Google Scholar · View at Scopus
  11. Y. Tanaka and N. Masumori, “Clinical follow-up of patients treated with propiverine hydrochloride for pollakisuria and/or urinary incontinence,” Japanese Journal of Urological Surgery, vol. 21, pp. 77–80, 2008. View at Google Scholar
  12. M. B. Chancellor, N. Zinner, K. Whitmore et al., “Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study,” Clinical Therapeutics, vol. 30, no. 10, pp. 1766–1781, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. E. Swift, P. Siami, and S. Forero-Schwanhaeuser, “Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: an open-label, flexible-dosing, multicentre study,” Clinical Drug Investigation, vol. 29, no. 5, pp. 305–316, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Onishi, M. Kato, and A. Hoshina, “The efficacy and safety for switchover treatment with second generation anti-muscarinic agent therapy in patients with overactive bladder,” J New Rem Clin, vol. 59, pp. 374–380, 2010. View at Google Scholar